Elizabeth A Salerno1,2, Eva Culakova3, Amber S Kleckner3,4, Charles E Heckler3,4, Po-Ju Lin3,4, Charles E Matthews2, Alison Conlin5, Lora Weiselberg6, Jerry Mitchell7, Karen M Mustian3,4, Michelle C Janelsins3,4. 1. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine in St Louis, St Louis, MO. 2. Division of Cancer Epidemiology and Genetics, Metabolic Epidemiology Branch, National Cancer Institute, Rockville, MD. 3. Department of Surgery, University of Rochester Medical Center, Rochester, NY. 4. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY. 5. Pacific Cancer Research Consortium-National Cancer Institute Community Clinical Oncology Research Program (NCORP), Seattle, WA. 6. North Shore LIJ Health System NCORP, Lake Success, NY. 7. Columbus NCORP, Columbus, OH.
Abstract
PURPOSE: Physical activity (PA) is a promising intervention for cancer-related cognitive decline, yet research assessing its use during chemotherapy is limited. This study evaluated patterns of PA before, during, and after chemotherapy in patients with breast cancer and the association between PA and cognitive function. METHODS: In a nationwide, prospective cohort study, we assessed PA (Aerobics Center Longitudinal Study PA measure) and perceived and objectively measured cognitive functioning (Functional Assessment of Cancer Therapy-Cognitive, Delayed Match to Sample, and Rapid Visual Processing measures) at prechemotherapy (T1), postchemotherapy (T2), and 6 months postchemotherapy (T3) in patients with breast cancer and cancer-free, age-matched controls at equivalent time points. Longitudinal linear mixed-effects models (LMMs) characterized PA changes over time between patients and controls, adjusting for demographic and clinical factors. LMMs further estimated the role of prechemotherapy PA and changes in PA during chemotherapy on cognitive changes over time. RESULTS: Patients with stage I-IIIC breast cancer (n = 580; age M [standard deviation] = 53.4 [10.6] years) and controls (n = 363; age M [standard deviation] = 52.6 [10.3] years) were included. One third of patients met national PA guidelines at T1, dropping to 21% at T2 before rising to 37% at T3. LMMs revealed declines in PA from T1 to T2 in patients compared with controls (all P < .001). Patients meeting guidelines at T1 demonstrated better cognitive scores over time on the Functional Assessment of Cancer Therapy-Cognitive and Rapid Visual Processing (all P < .05), with similar patterns of objectively-measured cognitive function as controls. In patients, greater moderate-to-vigorous PA at the previous time point was significantly associated with better cognitive trajectories (all P < .05), and adherence to PA guidelines throughout chemotherapy was associated with better self-reported cognition (P < .01). CONCLUSION: This nationwide study demonstrates that PA maintenance before and during chemotherapy is associated with better cognitive function immediately and 6 months after chemotherapy completion.
PURPOSE: Physical activity (PA) is a promising intervention for cancer-related cognitive decline, yet research assessing its use during chemotherapy is limited. This study evaluated patterns of PA before, during, and after chemotherapy in patients with breast cancer and the association between PA and cognitive function. METHODS: In a nationwide, prospective cohort study, we assessed PA (Aerobics Center Longitudinal Study PA measure) and perceived and objectively measured cognitive functioning (Functional Assessment of Cancer Therapy-Cognitive, Delayed Match to Sample, and Rapid Visual Processing measures) at prechemotherapy (T1), postchemotherapy (T2), and 6 months postchemotherapy (T3) in patients with breast cancer and cancer-free, age-matched controls at equivalent time points. Longitudinal linear mixed-effects models (LMMs) characterized PA changes over time between patients and controls, adjusting for demographic and clinical factors. LMMs further estimated the role of prechemotherapy PA and changes in PA during chemotherapy on cognitive changes over time. RESULTS: Patients with stage I-IIIC breast cancer (n = 580; age M [standard deviation] = 53.4 [10.6] years) and controls (n = 363; age M [standard deviation] = 52.6 [10.3] years) were included. One third of patients met national PA guidelines at T1, dropping to 21% at T2 before rising to 37% at T3. LMMs revealed declines in PA from T1 to T2 in patients compared with controls (all P < .001). Patients meeting guidelines at T1 demonstrated better cognitive scores over time on the Functional Assessment of Cancer Therapy-Cognitive and Rapid Visual Processing (all P < .05), with similar patterns of objectively-measured cognitive function as controls. In patients, greater moderate-to-vigorous PA at the previous time point was significantly associated with better cognitive trajectories (all P < .05), and adherence to PA guidelines throughout chemotherapy was associated with better self-reported cognition (P < .01). CONCLUSION: This nationwide study demonstrates that PA maintenance before and during chemotherapy is associated with better cognitive function immediately and 6 months after chemotherapy completion.
Authors: Mackenzi Pergolotti; Nicolò Matteo Luca Battisti; Lynne Padgett; Alix G Sleight; Maya Abdallah; Robin Newman; Kathleen Van Dyk; Kelley R Covington; Grant R Williams; Frederiek van den Bos; YaoYao Pollock; Elizabeth A Salerno; Allison Magnuson; Isabella F Gattás-Vernaglia; Tim A Ahles Journal: J Geriatr Oncol Date: 2019-10-14 Impact factor: 3.599
Authors: Theresa Crowgey; Katherine B Peters; Whitney E Hornsby; Amy Lane; Frances McSherry; James E Herndon; Miranda J West; Christina L Williams; Lee W Jones Journal: Appl Physiol Nutr Metab Date: 2013-12-03 Impact factor: 2.665
Authors: Ian M Lahart; George S Metsios; Alan M Nevill; Amtul R Carmichael Journal: Int J Environ Res Public Health Date: 2014-05-20 Impact factor: 3.390
Authors: Philipp Zimmer; Freerk T Baumann; Max Oberste; Peter Wright; Alexander Garthe; Alexander Schenk; Thomas Elter; Daniel A Galvao; Wilhelm Bloch; Sven T Hübner; Florian Wolf Journal: Biomed Res Int Date: 2016-04-10 Impact factor: 3.411
Authors: A M May; E M Monninkhof; E W Koevoets; S B Schagen; M B de Ruiter; M I Geerlings; L Witlox; E van der Wall; M M Stuiver; G S Sonke; M J Velthuis; J J Jobsen; M B E Menke-Pluijmers; E Göker; C C van der Pol; M E M M Bos; L W Tick; N A van Holsteijn; J van der Palen Journal: Breast Cancer Res Date: 2022-05-26 Impact factor: 8.408